Recap: Redhill Biopharma Q1 Earnings

Shares of Redhill Biopharma RDHL rose 4.6% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share decreased 66.67% year over year to ($0.05), which beat the estimate of ($0.24).

Revenue of $1,056,000 decreased by 39.21% from the same period last year, which missed the estimate of $4,380,000.

Looking Ahead

Redhill Biopharma hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: May 27, 2020

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/cgzdt8vg

Technicals

Company's 52-week high was at $9.12

52-week low: $3.26

Price action over last quarter: Up 51.80%

Company Profile

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.